Trial Profile

A Dose-escalation and Phase IIa Study of TG6002 Plus Flucytosine in Patients With Unresectable Colorectal Cancer With Liver Metastases

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 01 Feb 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

31 Jan 2024 This trial has been Completed in France, According to European Clinical Trials Database record.
21 Jun 2023 Status changed from recruiting to discontinued. Study has been terminated after Phase I part on 23 February 2023.
19 Apr 2023 Results(n=15) assessing safety and activity after intrahepatic artery administration TG6002 in patients with liver-dominant metastatic colorectal cancer presented at the 114th Annual Meeting of the American Association for Cancer Research

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com